Benitec Biopharma Inc. (BNTC): Price and Financial Metrics
BNTC Price/Volume Stats
| Current price | $0.25 | 52-week high | $2.10 |
| Prev. close | $0.25 | 52-week low | $0.13 |
| Day low | $0.23 | Volume | 78,100 |
| Day high | $0.25 | Avg. volume | 339,157 |
| 50-day MA | $0.22 | Dividend yield | N/A |
| 200-day MA | $0.27 | Market Cap | 6.96M |
BNTC Stock Price Chart Interactive Chart >
BNTC Stock Summary
- BNTC has a higher market value than only 2.14% of US stocks; more precisely, its current market capitalization is $5,820,081.
- BNTC's price/sales ratio is 85.59; that's higher than the P/S ratio of 97.34% of US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for BNTC comes in at -307.28% -- higher than that of only 1.75% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to BENITEC BIOPHARMA INC, a group of peers worth examining would be IKT, SABS, GNFT, BLDP, and BYSI.
- BNTC's SEC filings can be seen here. And to visit BENITEC BIOPHARMA INC's official web site, go to www.benitec.com.
BNTC Valuation Summary
- BNTC's price/earnings ratio is -0.3; this is 101.24% lower than that of the median Healthcare stock.
- BNTC's price/sales ratio has moved up 70.1 over the prior 94 months.
Below are key valuation metrics over time for BNTC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BNTC | 2023-05-23 | 86.8 | 1.3 | -0.3 | 0 |
| BNTC | 2023-05-22 | 82.4 | 1.2 | -0.3 | 0 |
| BNTC | 2023-05-19 | 85.3 | 1.2 | -0.3 | 0 |
| BNTC | 2023-05-18 | 80.9 | 1.2 | -0.3 | 0 |
| BNTC | 2023-05-17 | 77.9 | 1.1 | -0.3 | 0 |
| BNTC | 2023-05-16 | 89.7 | 1.3 | -0.3 | 0 |
BNTC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BNTC has a Quality Grade of F, ranking ahead of 1.09% of graded US stocks.
- BNTC's asset turnover comes in at 0.004 -- ranking 417th of 680 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows BNTC's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.004 | 1 | -36.612 |
| 2020-06-30 | 0.007 | 1 | -8.634 |
| 2019-06-30 | 0.718 | 1 | 2.070 |
| 2018-06-30 | 0.214 | 1 | -3.387 |
| 2017-06-30 | 0.521 | 1 | -2.375 |
| 2016-06-30 | 0.020 | 1 | -18.246 |
BNTC Price Target
For more insight on analysts targets of BNTC, see our BNTC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $14.00 | Average Broker Recommendation | 2 (Hold) |
Benitec Biopharma Inc. (BNTC) Company Bio
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.
Latest BNTC News From Around the Web
Below are the latest news stories about BENITEC BIOPHARMA INC that investors may wish to consider to help them evaluate BNTC as an investment opportunity.
Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update9 subjects enrolled into the OPMD clinical development programHAYWARD, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Third Fiscal Quarter ended March 31, 2023. The Company has filed its quarterly report on Form 10-Q for the |
Benitec Biopharma to Present at the OPMD International Conference9 OPMD subjects are now enrolled on the Natural History (NH) StudyHAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec will present virtually on the BB-301 |
Benitec Biopharma to Present at the JMP Securities Life Sciences ConferenceHAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec will present at the JMP Securities Life Sciences Conference on Tuesday, May 16th, 2023 at 2:00 pm ET. |
Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational UpdateFirst subject enrolled into the OPMD clinical development programHAYWARD, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Second Fiscal Quarter ended December 31, 2022. The Company has filed its quarterly report on Form 10-Q |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to start the day with a breakdown of the biggest pre-market stock movers investors will want to watch on Tuesday! |
BNTC Price Returns
| 1-mo | 17.92% |
| 3-mo | -21.88% |
| 6-mo | 31.58% |
| 1-year | -72.83% |
| 3-year | -96.65% |
| 5-year | -99.34% |
| YTD | 47.06% |
| 2022 | -93.51% |
| 2021 | -12.67% |
| 2020 | -60.78% |
| 2019 | -66.00% |
| 2018 | -49.32% |
Continue Researching BNTC
Want to see what other sources are saying about Benitec Biopharma LTD's financials and stock price? Try the links below:Benitec Biopharma LTD (BNTC) Stock Price | Nasdaq
Benitec Biopharma LTD (BNTC) Stock Quote, History and News - Yahoo Finance
Benitec Biopharma LTD (BNTC) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...